MTBVAC not checked
Bharat Biotech International Limited · BBV169
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MTBVAC (BBV169) vaccine is a freeze-dried powder containing live attenuated Mycobacterium tuberculosis (M. tb), which is presented as a lyophilized product in a 10- dose vial. After reconstitution with 1.0 mL sterile water for injection, one dose (0.1mL) of vaccine contains 5 x10\^5 CFU live attenuated M. tb. One dose (0.1mL) of the MTBVAC (BBV169) vaccine is to be administered in the right…”In the company’s words, NCT06997367 on ClinicalTrials.gov
- Tested for
- Tuberculosis (TB)
- Main trialPhase 2
- “Phase II trial to establish the safety, reactogenicity, and immunogenicity of the MTBVAC with a licensed BCG vaccine as a comparator in both TB naïve (QFT PLUS negative) and TB exposed (QFT PLUS positive) healthy adults and adolescents.”In the company’s words, NCT06997367 on ClinicalTrials.gov
- Other names
- BBV169
Other drugs for Tuberculosis (TB)
- QuabodepistatOtsuka · Phase 3
- MTBVACBiofabri, S.L · Phase 3
- SudapyridineShanghai Jiatan Pharmatech Co., Ltd · Phase 3
- RBCG-N-RSVBiothervax SpA · Phase 2
- BNT164a1BioNTech · Phase 1/2
- BNT164b1BioNTech · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 Sep 2025 | Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026